A reliable technology applicable to most cancers
What challenges does Oncosema tackle ?
CTC represent a powerful non-invasive measurable biomarker for all types of solid tumors at all stages. However, their rarity coupled with the lack of sensitivity, specificity and reliability of current techniques have limited their use in clinical practice to metastatic cancers so far.
Oncosema patented technology can capture and detect CTC in blood or other body fluids by targeting innovative and highly specific surface glycan marker called TACA (Tumor Associated Carbohydrate Antigens).
Oncosema technology assets
Specificity
Targets markers (TACA) that are exclusively present on CTC (and totally absent from normal cells)Sensitivity
Detects as low as 3 CTC among tens of billions normal blood cellsBroad spectrum
Sorts CTC shed by tumor from any organsPreserve viability
Preserves CTC viability, allowing various downstream analyses
